论文部分内容阅读
长期以来,人们一直都在猜想,肺泡表面活性物质可能对支气管肺炎起防御作用,主要根据有3:①根据一般经验,肺炎的肺泡腔内通常没有微生物,肺泡表面活性物质的结构仍然正常。最近,Morgen-roth 通过精密电镜的研究给以证实.②实验发现在人类巨噬细胞表面活性物质能诱发吞噬作用,在细胞内杀死肺炎球菌(但对葡萄球菌无作用),并具有调理作用。③Somerson 等通过离体鼠肺绘制出肺顺应性曲线图,与对照组相比,感染肺炎支原体的试验鼠,其肺弹性阻力明显减弱。
It has long been suspected that alveolar surfactant may have a defensive effect on bronchopneumonia, which is mainly based on the 3: ① According to the general experience, the alveolar cavity of pneumonia usually has no microbes and the structure of the alveolar surfactant remains normal. Recently, Morgen-roth was confirmed by the study of precision electron microscopy.② It has been found that the surface active substances in human macrophages can induce phagocytosis, kill pneumococci in cells (but have no effect on staphylococci) and have a conditioning effect . (3) Somerson et al. Mapped lung compliance curves by isolated rat lungs. Compared with the control group, the test mice infected with Mycoplasma pneumoniae showed significantly lower pulmonary elastic resistance.